Total structures of 13 minor components of bacitracin (BC) were proposed, and their antimicrobial activities were investigated. The components of BCincluding bacitracins A (BC-A) and F (BC-F) were isolated by preparative HPLCand were hydrolyzed under acidic conditions.
proposed structures of the BCminor componentsare incorrect; therefore, the structures were corrected based on these results. The structures of the BCminor componentswere the same as that of BCs-A and -F except that one to three of the L-isoleucines, including the TV-terminal one, were replaced by L-valines. These structures were confirmed by tandem mass spectrometry under fast atom bombardment (FAB) conditions and Frit-FAB liquid chromatography/mass spectrometry. Based on the UVspectra of the BC components determined by photodiode array detection-HPLC analysis, a new systematic nomenclature was proposed for the minor components. The isolated components were also used for the determination of their minimal inhibition concentrations and it was found that BC-Ais 2~8 times more potent than the other minor componentsagainst strains of Micrococcus luteus and Staphylocoecusaureus.
Bacitracin (BC) is a peptide antibiotic produced by Bacillus subtilis and B. licheniformis that exhibits activity against Gram-positive organisms1}. BCis a complex of many similar compounds and bacitracin A (BC-A) is a main component with the most potent activity among the components2~5). BC-F is a degradation product of BC-Athat shows no antibiotic activity and is nephrotoxic6'7). The structures of the above two components were elucidated8'9) and their biological properties are well known. However, in spite of some trials for characterization4~6), the structures and biological properties of other minor components have remained unresolved for over 40 years. To terminate these problems, we have been carrying out a series of studies concerning the separation and characterization of BC minor components1°~14>.
Since the discovery of BC in 1943, many researchers have tried to isolate and characterize its components. In 1948, Barry et al.2) reported that BCis separable into 3 or more components by countercurrent distribution (CCD) and the main component yields 9 amino acids by acid hydrolysis. A few years later, Craig et al.^and Newton et al.5) established new CCDconditions and separated BC into 5 and 10 components, respectively, another between 1953 and 1957 but they were all unsatisfactory. The final and well accepted structure of BC-A was proposed8) by Ressler and Kashelikar in 1966 , and the structure was partially confirmed by synthesis30~38).
The suggestion that BC-F is a degradation product of BC-Awas made by Craig et al.** who explained the conversion from BC-Ato -F by oxidation of the TV-terminal amino thiazoline moiety to a keto-thiazole6).
The structure of BC-F has been completely confirmed by synthesis39*. A few partial structures of other minor componentshave also been reported. Craig et al6) suggested that the structure of BC-B is the same as that of BC-A except that one isoleucine residue was replaced by valine, however the exact location of this substitution was unknown. They also suggested that BC-B is transformable to a BC-F type component. On the other hand, Newton et al.5) reported that BCs-B, -D and -E yield valines by hydrolysis and these components show the same UV absorption spectra as does BC-A, suggesting structural similarity among them. In addition, they reported that two groups of components, show the same UVspectra as each other. BCs-B, -C, -D and -E were reported to be antimicrobially active but to be less potent than BC-A4'5'40~42 Thus, the BCcomponents were separated into more than 30 peaks on the HPLCchromatogram as shown in Fig.  1 . Preparative separation of 50mgof a commercial BC complex gave BCs-Aand -F in a pure state within a few hours by HSCCC12). Although other fractions containing minor componentswere still mixtures, they were highly enriched by this operation. These isolated and enriched components were useful for characterization of the minor componentsin previous and present studies.
In addition, we characterized the minor components by using Frit-FAB LC/MS13), and the structures of 13 minor components containing BC-B were proposed14) as follows: the minor componentsare classified into two groups; BC-Aand BC-F related components, depending on their commonTV-terminal moieties. The structures of BC-Arelated components are the same as that of BC-A except that one to three of the leucine or isoleucine residues have been replaced by valines. The BC-F related MAR. 1995 components are the degradation products of the BC-A related components that have gone through the same degradation process as BC-A. This is the first time the total structures of BCminor components, except for that ofBC-F, have been proposed since the discovery ofBC. 
Isolation and Separation of Minor Components
The isolation of the minor components was carried out by preparative HPLC.The original mixtures of the minor components, enriched BC-A and BC-F related components were used14). The BC-A related components were separated on a Chromatorex Phenyl HPLCcolumn (5/an, 250 x 20.0mm i.d.) (Fuji-Silysia Ltd., Kasugai, Japan) using acetonitrile -0.01 m TFAaqueous solution (23:73) as the mobile phase at a flow rate of 10.0 ml/minute. The eluent was monitored at 234 nm, and eluents of the corresponding peaks were collected and lyophilized, after removing the acetonitrile using a rotary evaporator, to yield each isolated component. The BC-F related componentswere isolated in the same way as described above except that an acetonitrile -0.01 m TFA aqueous solution (38 : 62) was used as the mobile phase.
To check the purity of the isolated components, the following HPLCconditions were used: column, Chro- 100 fi\ of distilled 6 n HC1aqueous solution. This solution was evaporated to dryness and the residue was dissolved in 50jA of water. The amino acids solution was transferred to a 2-ml reaction vial, and 20^1 of 1m NaHCO3 aqueous solution and 100/d of 1% FDAA acetone solution were added to the vial. The vials were capped and incubated at 37°C for 60 minutes in a water bath. After the addition of 20{A of 1n HC1 aqueous solution to the vial to stop the reaction, the reaction mixture was evaporated to dryness. The residual derivatized amino acids were dissolved in 1ml of methanol and 2 /il aliquots of this solution were injected into the HPLCsystem. The separation was performed on a Inertsil C8 HPLC column (5/im, 150 x 4.6mm i.d.)
(GL-Science, Tokyo, Japan) using an acetonitrile-0.01 m TFA aqueous solution as a mobile phase under gradient elution mode (acetonitrile, 20%~40%, 30 minutes followed by hold at 40% for 10 minutes). The flow rate of the mobile phase was 1.0 ml/minute and the monitoring wavelength was set at 340 nm.
Measurement of MS/MSSpectra
MS/MSwas carried out using a JMS-HX/HX110A tandem mass spectrometer (JEOL, Tokyo, Japan the resulting product ions were separated and detected at the second mass spectrometer. The product ion spectra were obtained by processing the mass data using a JMA-DA7000data system (JEOL). The fast atom beam was operated at 6 kV using xenon gas and the first mass spectrometer was operated at a lOkV accelerating potential. The floating cell was used at a voltage of 5 kV. A mixture of glycerol and In HC1 (1:1) was used as the matrix for the ionization of the samples under FABconditions, and helium was used as the collision gas. containing a series of concentrations (25~0.05jUg/ml) of samples, the suspension of individual test strains (105~106 cell/ml) were inoculated by micromanipulator (MIT-P, SAKURA, Tokyo, Japan). The growth of the strains was observed after incubation at 37°C for 20 hours.
Determination of Minimal Inhibition Concentration
Results and Discussion Determination of the Absolute Configuration of the Constituent Amino Acids
To determine the absolute configuration of the constituent aminoacids of BCcomponents, components including BCs-A and -F were isolated by preparative HPLCand the purity of the isolated components (peaks No. 7, 10, ll, 12, 13, 15, 16, 24, 25, 26, 27, 28, 29and 31 as indicated in Fig. 1 Table 1 were considered to be all D-alloisoleucines derived from TV-terminal L -isoleucines. If so, the D-valines in Table 1 could also be artifacts derived from TV-terminal amino acids by way of the same mechanismas that of D-alloisoleucine as shownin Fig et al.44\ Morris45) and Siegel et al^but also point out that our previously proposed structures of BC minor components14) are incorrect with respect to one substitution position of valine at the TV-terminus. In addition, the following suggestion was also given: all components have the commonstructure shown in Fig.  4 and are different from one another only in the structures of the N-terminal moieties and that the constituent amino acids at the "X" and "Y" positions are L-isoleucine or l-valine. The variations of the constituent amino acids and TV-terminal moieties among the components are summarized in Table 3 .
Confirmation of Proposed Structures by LC/MS and MS/MS
To confirm the structures proposed above, previous Frit-FAB LC/MSdata14) were reexamined. Because BC Table 3 . Proposed structures and names for BCcomponents.
components yield characteristic fragment ions at mjz 1 57, 171, 182, 196, 185 and 199 from their TV-terminal moieties under FABconditions, as shown in Fig. 3 , these ions were used for mass chromatography. The fragment ion at m/z 185 could not be successfully monitored because it overlapped with a very intensive background ion from the glycerol used as a matrix. Because the mass Wepreviously applied MS/MSto structural characterization of isolated BC-Aand -F under FABconditions, and satisfactory product ion spectra containing many sequence ions were obtained12). In order to confirm the structures of BC-Arelated components proposed above, the isolated components were analyzed by MS/MSand the fragment ions in the product ion spectra were examined in detail. In the product ion spectra of BC-A many structurally informative fragment ions such as immoniumions originating from each constituent amino acid (ornithine, lysine, leucine/isoleucine, glutamic acid, histidine and phenylalanine at m/z 70, 84, 86, 102, 110 and 120, respectively), C-terminal ions (a3 and b4) and iV-terminal ions (yl5 y2, v3, v4 and v5)50) were observed as shown in Fig. 6 (A) . Because the BC-A related components give the same fragmentation pattern as that of BC-A, their product ion spectra were examined in detail for immoniumions and sequence ions as shown in Table 4 . As shown in Fig. 6 (B) , all of the expected C-terminal and TV-terminal sequence ions and immonium ions containing valine at m/z 72 were observed in each spectrum of BC-Arelated components. Thus, based on the LC/MSand MS/MSresults, the proposed structures of BCminorcomponents weresupported.
Designation of BCComponents The names of BC components such as BCs-Dand -E were originally proposed by Newton et al.3'5) and the naming has been well accepted until the present time.
They also reported that BCs-A, -B, -D and -E show the same broad absorption maximumat 253 nmdue to their thiazoline ring moiety, and that BCs-F1? -F2 and -F3 absorb at 288nm due to their thiazole ring, though BCs-C and -G show a sharp maximumat 250nm5). Because the nomenclature was based on the CCD separation, it is not adaptable to the study of components separated by HPLC. Therefore, we would like to propose a newsystematic nomenclaturein line with the original one. Comparing the HPLCprofile shown in Fig. 1 with previous CCDelution curves5), it was found that the minor components with molecular weights (M.W.) of 1407 (peaksNo. 12, 13 and 15), 1393 (No. 7, 10and ll), 1379 (No. 6), 1404 (No. 27, 28 and 29) and 1390 correspond to BCs-B, -D, -E, -F2 and -F3, respectively. To confirm these correspondences, UV absorption spectra of BCcomponentswere measuredby photodiode-array detection HPLC. The components of 6, 7, 10, ll, 12, 13, 15 and 16, andpeaksNo. 24, 25, 26, 27, 28, 29 and 31 Comparison of the MICsand the proposed structures of the minor componentssuggest that the location of the valine affects the activity of each component in the following decreasing order: TV-terminus, the seven membered peptide ring, and the side chain peptide moiety. Because this order is related to the elution order of the minor components on the HPLC, the activity may depend on the hydrophobicity of the respective component.
C onclusion
The total structures of 13 minor components of bacitracin, including the absolute configuration of the constituent amino acids, were proposed following the results of structural characterization of the isolated components using techniques of amino acid analysis, LC/MS and MS/MS. The structures of the BC-A related components were the same as that of BC-Aexcept that one to three of the L-isoleucines, including the N-terminal one, were replaced by L-valines. The BC-F related components were the degradation products of BC-A related components that went through the same degradation process as BC-A. These results agree with the proposals of Tetler et al^\ Morris45) and Siegel et al.46\ but are in contrast with our earlier suggestions14). Among the minor components described above, the three isobaric (MW 1407) components are named as BCs-Bl5 -B2 and -B3, those ofMW 1393, 1404 and 1390
are named as BCs-D1? -D2 and -D3, BCs-H^-H2 and -H3, and BCs-I1? -I2 and -I3, respectively, in line with their original names as much as possible. For the component of MW1379 its original name, BC-E, is still used. The antimicrobial activity of isolated components against some strains was determined and the results suggest that the location of valine affects the activity of the component in the following order: TV-terminus, the seven memberedpeptide ring and the side chain peptide moiety.
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